Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine
- Details
- Category: Novartis
Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor (VEGF), a key mediator of angiogenesis in cancer, and is used in combination with other treatments(1,2).
SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
- Details
- Category: GlaxoSmithKline
SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination with GSK's pandemic adjuvant following positive interim Phase 1/2 results.
Lilly and Lycia Therapeutics enter into strategic collaboration to discover and develop novel lysosomal targeting chimera (LYTAC) degraders
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology.
AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
- Details
- Category: AstraZeneca
Positive high-level results from the PROVENT Phase III pre-exposure prophylaxis trial showed AstraZeneca's AZD7442 achieved a statistically significant reduction in the incidence of symptomatic COVID-19, the trial's primary endpoint.
AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by 77% (95% confidence interval (CI): 46, 90), compared to placebo.
Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrates improved immune response and protection in preclinical study
- Details
- Category: GlaxoSmithKline
CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and GSK announced the publication of preclinical data investigating immune responses as well as the protective efficacy of CureVac's first-generation vaccine candidate, CVnCoV, and second-generation vaccine candidate, CV2CoV, against SARS-CoV-2 challenge in non-human primates.
Pfizer and BioNTech announce submission of initial data to U.S. FDA to support booster dose of COVID-19 vaccine
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they have submitted Phase 1 data to the U.S. Food and Drug Administration (FDA) to support the evaluation of a third, or booster, dose of the companies' COVID-19 vaccine (BNT162b2) for future licensure. These data also will be submitted to the European Medicines Agency (EMA) and other regulatory authorities in the coming weeks.
VTX-801 receives U.S. FDA Fast Track designation for the treatment of Wilson Disease
- Details
- Category: Pfizer
Vivet Therapeutics ("Vivet"), a clinical-stage biotechnology company, and Pfizer Inc. (NYSE: PFE) announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VTX-801, Vivet's clinical-stage gene therapy for the treatment of Wilson Disease - a rare, genetic disorder that reduces the ability of the liver and other tissues to regulate copper levels, causing severe hepatic damage, neurological symptoms, and potentially death.
More Pharma News ...
- Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
- Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development
- Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation
- GSK and Vir Biotechnology announce Joint Procurement Agreement with European Commission for COVID-19 treatment, sotrovimab
- Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people
- Pfizer and BioNTech to provide U.S. government with an additional 200 million doses of COVID-19 vaccine
- AstraZeneca and Regeneron to research, develop and commercialise new small molecule medicines for obesity